Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge.

Cash DM, Frost C, Iheme LO, Ünay D, Kandemir M, Fripp J, Salvado O, Bourgeat P, Reuter M, Fischl B, Lorenzi M, Frisoni GB, Pennec X, Pierson RK, Gunter JL, Senjem ML, Jack CR Jr, Guizard N, Fonov VS, Collins DL, Modat M, Cardoso MJ, Leung KK, Wang H, Das SR, Yushkevich PA, Malone IB, Fox NC, Schott JM, Ourselin S.

Neuroimage. 2015 Dec;123:149-64. doi: 10.1016/j.neuroimage.2015.07.087. Epub 2015 Aug 11.

2.

Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity.

Wesnes KA.

Alzheimers Res Ther. 2014 Aug 29;6(5):58. doi: 10.1186/s13195-014-0058-1. eCollection 2014. Review.

3.

The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease.

Shah RC, Kamphuis PJ, Leurgans S, Swinkels SH, Sadowsky CH, Bongers A, Rappaport SA, Quinn JF, Wieggers RL, Scheltens P, Bennett DA.

Alzheimers Res Ther. 2013 Nov 26;5(6):59. doi: 10.1186/alzrt224. eCollection 2013.

4.

Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future.

Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, Evans J, Lee M, Porsteinsson A, Lanctôt KL, Rosenberg PB, Sultzer DL, Francis PT, Brodaty H, Padala PP, Onyike CU, Ortiz LA, Ancoli-Israel S, Bliwise DL, Martin JL, Vitiello MV, Yaffe K, Zee PC, Herrmann N, Sweet RA, Ballard C, Khin NA, Alfaro C, Murray PS, Schultz S, Lyketsos CG; Neuropsychiatric Syndromes Professional Interest Area of ISTAART.

Alzheimers Dement. 2013 Sep;9(5):602-8. doi: 10.1016/j.jalz.2012.12.001. Epub 2013 Apr 3. Review.

5.

Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice.

Holthoff VA, Ferris S, Ihl R, Robert P, Winblad B, Gauthier S, Sternberg K, Tennigkeit F.

Alzheimers Res Ther. 2011 Jul 6;3(5):27. doi: 10.1186/alzrt89.

6.

Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 2.

Evans DA, Grodstein F, Loewenstein D, Kaye J, Weintraub S.

Alzheimers Dement. 2011 Jan;7(1):110-23. doi: 10.1016/j.jalz.2010.11.008.

7.

A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.

Palmqvist S, Minthon L, Wattmo C, Londos E, Hansson O.

Alzheimers Res Ther. 2010 Oct 15;2(5):29. doi: 10.1186/alzrt53.

8.

Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?

Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F.

Alzheimers Res Ther. 2010 Aug 26;2(4):24. doi: 10.1186/alzrt48.

9.

Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.

Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, Tremont G; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2010 Jun;67(6):688-96. doi: 10.1001/archneurol.2010.118.

10.

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?

Blennow K, Zetterberg H.

Alzheimers Res Ther. 2010 Apr 30;2(2):8. doi: 10.1186/alzrt31.

11.

Performance-based measures of everyday function in mild cognitive impairment.

Goldberg TE, Koppel J, Keehlisen L, Christen E, Dreses-Werringloer U, Conejero-Goldberg C, Gordon ML, Davies P.

Am J Psychiatry. 2010 Jul;167(7):845-53. doi: 10.1176/appi.ajp.2010.09050692. Epub 2010 Apr 1.

Supplemental Content

Support Center